These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 8946812)

  • 21. Late lumen loss after coronary angioplasty is associated with the activation status of circulating phagocytes before treatment.
    Pietersma A; Kofflard M; de Wit LE; Stijnen T; Koster JF; Serruys PW; Sluiter W
    Circulation; 1995 Mar; 91(5):1320-5. PubMed ID: 7867168
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Restenosis or rapid progression in non-dilated sites are not predictors of late spontaneous coronary events.
    Benchimol D; Dubroca B; Dufourq P; Benchimol H; Couffinhal T; Dartigues JF; Bonnet J
    Int J Cardiol; 1997 Jul; 60(2):201-11. PubMed ID: 9226292
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Restenosis after transluminal coronary angioplasty: a risk factor analysis.
    Gürlek A; Dağalp Z; Oral D; Omürlü K; Erol C; Akyol T; Tutar E
    J Cardiovasc Risk; 1995 Feb; 2(1):51-5. PubMed ID: 7606641
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Risk factors, time course and treatment effect for restenosis after successful percutaneous transluminal coronary angioplasty of chronic total occlusion.
    Ellis SG; Shaw RE; Gershony G; Thomas R; Roubin GS; Douglas JS; Topol EJ; Startzer SH; Myler RK; King SB
    Am J Cardiol; 1989 Apr; 63(13):897-901. PubMed ID: 2522727
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Restenosis after delayed coronary angioplasty of the culprit vessel in patients with a recent myocardial infarction treated by thrombolysis.
    Bauters C; Khanoyan P; McFadden EP; Quandalle P; Lablanche JM; Bertrand ME
    Circulation; 1995 Mar; 91(5):1410-8. PubMed ID: 7867181
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Lesion-related factors associated with restenosis after percutaneous transluminal coronary angioplasty in the absence of patient-related factors].
    Sakai Y; Tomobuchi Y; Hashizume T; Imanishi T; Tomimoto S; Toyoda Y; Arita M; Hano T; Nishio I
    J Cardiol; 1997 Jan; 29(1):1-6. PubMed ID: 9023673
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Differences in restenosis propensity of devices for transluminal coronary intervention. A quantitative angiographic comparison of balloon angioplasty, directional atherectomy, stent implantation and excimer laser angioplasty. CARPORT, MERCATOR, MARCATOR, PARK, and BENESTENT Trial Groups.
    Foley DP; Melkert R; Umans VA; de Jaegere PP; Strikwerda S; de Feyter PJ; Serruys PW
    Eur Heart J; 1995 Oct; 16(10):1331-46. PubMed ID: 8746901
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prevention of restenosis after coronary balloon angioplasty: rationale and design of the Fluvastatin Angioplasty Restenosis (FLARE) Trial. The FLARE Study Group.
    Foley DP; Bonnier H; Jackson G; Macaya C; Shepherd J; Vrolix M; Serruys PW
    Am J Cardiol; 1994 May; 73(14):50D-61D. PubMed ID: 8198025
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Failure of epoprostenol (prostacyclin, PGI2) to inhibit platelet aggregation and to prevent restenosis after coronary angioplasty: results of a randomised placebo controlled trial.
    Gershlick AH; Spriggins D; Davies SW; Syndercombe Court YD; Timmins J; Timmis AD; Rothman MT; Layton C; Balcon R
    Br Heart J; 1994 Jan; 71(1):7-15. PubMed ID: 8297699
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effectiveness of an antioxidant in preventing restenosis after percutaneous transluminal coronary angioplasty: the Probucol Angioplasty Restenosis Trial.
    Yokoi H; Daida H; Kuwabara Y; Nishikawa H; Takatsu F; Tomihara H; Nakata Y; Kutsumi Y; Ohshima S; Nishiyama S; Seki A; Kato K; Nishimura S; Kanoh T; Yamaguchi H
    J Am Coll Cardiol; 1997 Oct; 30(4):855-62. PubMed ID: 9316509
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Impaired fibrinolysis early after percutaneous transluminal coronary angioplasty is associated with restenosis.
    Sakata K; Miura F; Sugino H; Shinobe M; Shirotani M; Yoshida H; Mori N; Hoshino T; Takada A
    Am Heart J; 1996 Jan; 131(1):1-6. PubMed ID: 8553994
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Hostility predicts restenosis after percutaneous transluminal coronary angioplasty.
    Goodman M; Quigley J; Moran G; Meilman H; Sherman M
    Mayo Clin Proc; 1996 Aug; 71(8):729-34. PubMed ID: 8691892
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Long-term luminal renarrowing after successful elective coronary angioplasty of total occlusions. A quantitative angiographic analysis.
    Violaris AG; Melkert R; Serruys PW
    Circulation; 1995 Apr; 91(8):2140-50. PubMed ID: 7697842
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Restenosis after percutaneous transluminal coronary angioplasty in the elderly--risk factor analysis].
    Ishikawa Y; Fujioka Y; Kitagawa Y; Nobusawa A; Takahashi A; Taniguchi T; Yokoyama M
    Nihon Ronen Igakkai Zasshi; 1995 Jul; 32(7):491-6. PubMed ID: 7500552
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Clinical and angiographic course after coronary angioplasty. Analysis of predictor factors of restenosis].
    Sanz E; Domingo E; Moreno V; Angel J; Anivarro I; Alió J; Alijarde M; Soler-Soler J
    Rev Esp Cardiol; 1992 Nov; 45(9):568-77. PubMed ID: 1475495
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Predictive factors of restenosis after multivessel percutaneous transluminal coronary angioplasty.
    Le Feuvre C; Bonan R; Lespérance J; Gosselin G; Joyal M; Crépeau J
    Am J Cardiol; 1994 May; 73(12):840-4. PubMed ID: 8184804
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effect of angiographic and hemodynamic results of coronary balloon angioplasty on late angiographic outcome.
    Liu MW; Roubin GS; King SB
    Am Heart J; 1994 Dec; 128(6 Pt 1):1077-83. PubMed ID: 7985587
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Therapeutic dissection after successful coronary balloon angioplasty: no influence on restenosis or on clinical outcome in 693 patients. The MERCATOR Study Group (Multicenter European Research Trial with Cilazapril after Angioplasty to prevent Transluminal Coronary Obstruction and Restenosis).
    Hermans WR; Rensing BJ; Foley DP; Deckers JW; Rutsch W; Emanuelsson H; Danchin N; Wijns W; Chappuis F; Serruys PW
    J Am Coll Cardiol; 1992 Oct; 20(4):767-80. PubMed ID: 1388181
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prior restenosis predicts restenosis after coronary angioplasty of a new significant narrowing.
    Bresee SJ; Jacobs AK; Garber GR; Ruocco NA; Mills RM; Bergelson BA; Ryan TJ; Faxon DP
    Am J Cardiol; 1991 Nov; 68(11):1158-62. PubMed ID: 1951074
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Detection of restenosis after successful coronary angioplasty: improved clinical decision making with use of a logistic model combining procedural and follow-up variables.
    Renkin J; Melin J; Robert A; Richelle F; Bachy JL; Col J; Detry JM; Wijns W
    J Am Coll Cardiol; 1990 Nov; 16(6):1333-40. PubMed ID: 2229783
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.